A multi-center, open-label, single-arm clinical study to assess effects of a 5-day regimen of
10 micrograms per kilogram (mcg/kg) of tbo-filgrastim administered subcutaneously daily on
the mobilization of cluster of differentiation 34+ (CD34+) cells in at least 60 healthy male
and female participants. The pharmacokinetics, pharmacodynamics, safety, tolerability, and
immunogenicity of tbo-filgrastim will be assessed.